On Monday, Gilead Sciences Inc. GILD and Merck & Co. Inc. MRK on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial ...
10don MSN
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Median overall survival for ivonescimab was 17.0 months vs. 14.0 months for placebo in Western patients. Ivonescimab plus chemo cut progression risk by 33% in Western patients and 45% in Chinese ...
Researchers found that Keytruda — the focus of ICIJ's recent Cancer Calculus investigation — accounted for nearly half of the ...
Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results